Comparative Pharmacology
Head-to-head clinical analysis: FYCOMPA versus VALPROATE SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FYCOMPA versus VALPROATE SODIUM.
FYCOMPA vs VALPROATE SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-competitive AMPA receptor antagonist; inhibits glutamate-mediated excitatory neurotransmission by selectively targeting AMPA receptors.
Increases GABA levels by inhibiting GABA transaminase and blocking voltage-gated sodium channels; also modulates T-type calcium channels.
Initial: 2 mg orally once daily; titrate weekly by 2 mg increments to maintenance dose of 4-12 mg once daily depending on seizure type and tolerability; maximum 12 mg once daily.
10-15 mg/kg/day orally or intravenously in 2-3 divided doses; increase by 5-10 mg/kg/day weekly to therapeutic range of 50-100 mcg/mL. Maximum dose 60 mg/kg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 105 hours (range 80-120 hours) in patients with epilepsy; supports once-daily dosing.
Terminal elimination half-life is 9–16 hours in adults; may be shorter in children (5–12 hours) and prolonged in hepatic impairment or elderly (up to 18 hours). Neonatal half-life: 10–67 hours. Clinically, twice-daily dosing is typical.
Renal: approximately 30% as unchanged drug; fecal: approximately 70% (mostly as metabolites, minimal unchanged).
Primarily renal (90% as glucuronide conjugates, 3-oxo derivative, and other metabolites; <3% unchanged). Biliary/fecal excretion accounts for <10%.
Category C
Category C
Anticonvulsant
Anticonvulsant